Researchers presented results from a simulation analysis that looked to identify the potential reduction in Medicare beneficiaries’ out-of-pocket costs through the use of biosimilar filgrastim-sndz (Zarxio, Sandoz) over the reference filgrastim at the 2018 San Antonio Breast Cancer Symposium held December 4-8, 2018, in San Antonio, Texas.
Researchers presented results from a simulation analysis that looked to identify the potential reduction in Medicare beneficiaries’ out-of-pocket costs through the use of biosimilar filgrastim-sndz (Zarxio, Sandoz) over the reference filgrastim at the 2018 San Antonio Breast Cancer Symposium held December 4-8, 2018, in San Antonio, Texas.
The analysis was based on data from more than 1600 claims and found that out-of-pocket expenditures were substantially less among Medicare beneficiaries with breast cancer undergoing chemotherapy who received prophylaxis for febrile neutropenia with biosimilar filgrastim over the reference product.
Researchers used ICD-10 codes to identify patients with breast cancer in this simulation, and Healthcare Common Procedure Coding System codes were used to identify those treated with filgrastim-sndz or the reference. The claims used in the simulation were extracted from the 2016 Medicare Limited Data Set. In total, the study authors extracted 233 claims for 300 mcg of biosimilar filgrastim (average price, $244.94) and 383 claims for 480 mcg of biosimilar filgrastim (average price, $421.15). Thus, the total number of included claims for filgrastim-sndz was 616, with a weighted average price of $362.79.
Conversely, 380 claims for 300 mcg of reference filgrastim were also extracted (average price, $283.92), and 684 claims for 480 mcg of reference filgrastim (average price, $478.32), for a total of 1064 claims at a weighted average price of $406.86.
In order to calculate the average Medicare payment to the provider and the average beneficiary out-of-pocket responsibility per claim for either product, researchers utilized Medicare’s payment calculation worksheet. According to the worksheet, beneficiaries were assumed to pay the provider 20% coinsurance; in the case of a secondary payer, the payment to the provider was 20% minus payment by the secondary provider.
Physicians were reimbursed by Medicare at 80% of the allowed cost for either product, with a 2% reduction calculated for prescriptions written during the sequestration period that began in 2013 and has continued ever since.
The total payment to the provider was found to be $221 for 300 mcg of filgrastim-sndz and $380 for 480 mcg of filgrastim-sndz, and $257 for 300 mcg of reference filgrastim and $433 for 480 mcg of reference filgrastim. Researchers found that the weighted average savings to Medicare for the use of filgrastim-sndz over the reference product was $32.87 per claim, reflecting the Medicare weighted average payments to providers of $284.06 and $316.93 per claim, respectively.
When extrapolated to 100,000 beneficiaries (1 million claims), the model estimated potential out-of-pocket savings to reach approximately $9.5 million for Medicare beneficiaries. Additionally, the study also found that Medicare saw reduced payments of $32.9 million.
“By weighted average, a beneficiary’s out-of-pocket responsibility for filgrastim-sndz was lower than that for reference filgrastim ($72.94 versus $82.45), creating a weighted average cost savings per claim of $9.51,” concluded the study authors.
Reference
Puckrein G, Xu L, Ryan A, et al. Potential Medicare beneficiary out-of-pocket cost reductions through use of biosimilar filgrastim-sndz over reference filgrastim among breast cancer patients: a simulation model analyses. Presented at: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. Abstract P5-15-05.
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.